Marginal Zone Lymphoma: FDA Updates

September 14, 2021 – The U.S. Food and Drug Administration (FDA) granted accelerated approval of zanubrutinib (BRUKINSA) for adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen. More Information.

February 5, 2021 – The U.S. Food and Drug Administration (FDA) approved umbralisib (UKONIQ), an oral kinase inhibitor including PI3K-delta and casein kinase CK1-epsilon, for adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen; and adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy. More Information.

May 28, 2019 – The U.S. Food and Drug Administration (FDA) approved the use of lenalidomide (REVLIMID) in combination with rituximab (RITUXAN) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) and marginal zone lymphoma (MZL). More Information.